Monopar Therapeutics, Inc. (MNPR)
59.27
-1.72
(-2.82%)
USD |
NASDAQ |
May 15, 16:00
59.42
+0.15
(+0.25%)
After-Hours: 20:00
Monopar Therapeutics Enterprise Value : 259.69M for May 15, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anika Therapeutics, Inc. | 183.10M |
| BioCryst Pharmaceuticals, Inc. | 2.911B |
| Plus Therapeutics, Inc. | 23.73M |
| Perspective Therapeutics, Inc. | 172.38M |
| AVITA Medical, Inc. | 168.20M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.893M |
| Total Expenses (Quarterly) | 3.893M |
| EPS Diluted (Quarterly) | -0.4561 |
| Earnings Yield | -3.49% |
| Normalized Earnings Yield | -3.486 |